Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
Investing.com -- MetLife Inc (NYSE:MET) shares fell 5.2% after the insurance giant reported second quarter earnings that fell short of analyst expectations, with adjusted earnings declining 16% YoY amid less favorable underwriting and lower investment margins.
The company reported adjusted earnings of $2.02 per share for the second quarter of 2025, missing the analyst estimate of $2.15. Revenue came in at $17.92 billion, below the consensus estimate of $18.55 billion. Total (EPA:TTEF) adjusted earnings declined to $1.4 billion from $1.6 billion in the same quarter last year.
Despite the earnings miss, MetLife saw 5% growth in adjusted premiums, fees and other revenues excluding pension risk transfers, which rose to $12.4 billion. Net investment income increased 9% to $5.7 billion, though variable investment income fell to $195 million, primarily due to lower private equity returns.
"While the quarter didn’t demonstrate the full earnings power of MetLife, we saw clear momentum across several of our market-leading businesses, coupled with solid underlying fundamentals," said Michel Khalaf, President and Chief Executive Officer.
The Group Benefits segment, which reported a 25% decline in adjusted earnings, was a particular weak spot due to less favorable underwriting across life and non-medical health products. The Asia segment also saw a 22% drop in adjusted earnings on both a reported and constant currency basis.
Bright spots included Latin America, where adjusted earnings rose 3% (15% on a constant currency basis), and EMEA, which posted a 30% increase in adjusted earnings, reflecting strong volume growth across the region.
The company returned approximately $900 million to shareholders through share repurchases and common stock dividends during the quarter. Book value per share increased 7% to $35.79, while adjusted book value per share rose 6% to $56.23.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.